Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Lymphoma

  Free Subscription


Articles published in Leukemia

Retrieve available abstracts of 61 articles:
HTML format
Text format



Single Articles


    September 2019
  1. WANG M, Rule S, Zinzani PL, Goy A, et al
    Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
    Leukemia. 2019 Sep 26. pii: 10.1038/s41375-019-0575.
    PubMed     Text format    


  2. STAIGER AM, Altenbuchinger M, Ziepert M, Kohler C, et al
    A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.
    Leukemia. 2019 Sep 17. pii: 10.1038/s41375-019-0573.
    PubMed     Text format     Abstract available


  3. SONG Y, Gao Q, Zhang H, Fan L, et al
    Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.
    Leukemia. 2019 Sep 13. pii: 10.1038/s41375-019-0545.
    PubMed     Text format     Abstract available


    August 2019
  4. DESCH AK, Hartung K, Botzen A, Brobeil A, et al
    Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma.
    Leukemia. 2019 Aug 20. pii: 10.1038/s41375-019-0541.
    PubMed     Text format     Abstract available


    June 2019
  5. VRZALIKOVA K, Ibrahim M, Vockerodt M, Perry T, et al
    Correction: S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells.
    Leukemia. 2019 Jun 25. pii: 10.1038/s41375-019-0511.
    PubMed     Text format     Abstract available


  6. ALKODSI A, Cervera A, Zhang K, Louhimo R, et al
    Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes.
    Leukemia. 2019 Jun 11. pii: 10.1038/s41375-019-0509.
    PubMed     Text format     Abstract available


    May 2019
  7. NAM J, Kim DU, Kim E, Kwak B, et al
    Disruption of the Myc-PDE4B regulatory circuitry impairs B-cell lymphoma survival.
    Leukemia. 2019 May 28. pii: 10.1038/s41375-019-0492.
    PubMed     Text format     Abstract available


  8. ZHU F, Guo H, Bates PD, Zhang S, et al
    PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
    Leukemia. 2019 May 23. pii: 10.1038/s41375-019-0489.
    PubMed     Text format     Abstract available


  9. JAIN T, Sauter CS, Shah GL, Maloy MA, et al
    Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.
    Leukemia. 2019 May 21. pii: 10.1038/s41375-019-0476.
    PubMed     Text format    


  10. LUPINO L, Perry T, Margielewska S, Hollows R, et al
    Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma.
    Leukemia. 2019 May 16. pii: 10.1038/s41375-019-0478.
    PubMed     Text format     Abstract available


  11. WATATANI Y, Sato Y, Miyoshi H, Sakamoto K, et al
    Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling.
    Leukemia. 2019 May 15. pii: 10.1038/s41375-019-0473.
    PubMed     Text format     Abstract available


  12. CRISTOFOLETTI C, Bresin A, Picozza M, Picchio MC, et al
    Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance.
    Leukemia. 2019;33:1231-1242.
    PubMed     Text format     Abstract available


  13. TORREY H, Khodadoust M, Tran L, Baum D, et al
    Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sezary syndrome.
    Leukemia. 2019;33:1206-1218.
    PubMed     Text format     Abstract available


    April 2019
  14. TIAN XP, Huang WJ, Huang HQ, Liu YH, et al
    Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma.
    Leukemia. 2019 Apr 5. pii: 10.1038/s41375-019-0466.
    PubMed     Text format     Abstract available


  15. PAPIN A, Tessoulin B, Bellanger C, Moreau A, et al
    CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.
    Leukemia. 2019 Apr 2. pii: 10.1038/s41375-019-0463.
    PubMed     Text format     Abstract available


    March 2019
  16. HARRINGTON CT, Sotillo E, Robert A, Hayer KE, et al
    Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.
    Leukemia. 2019 Mar 26. pii: 10.1038/s41375-019-0454.
    PubMed     Text format     Abstract available


  17. ARAF S, Wang J, Korfi K, Pangault C, et al
    Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.
    Leukemia. 2019 Mar 23. pii: 10.1038/s41375-019-0425.
    PubMed     Text format     Abstract available


  18. SASI BK, Martines C, Xerxa E, Porro F, et al
    Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
    Leukemia. 2019 Mar 14. pii: 10.1038/s41375-019-0442.
    PubMed     Text format     Abstract available


  19. NGUYEN PH, Niesen E, Hallek M
    New roles for B cell receptor associated kinases: when the B cell is not the target.
    Leukemia. 2019;33:576-587.
    PubMed     Text format     Abstract available


    January 2019
  20. VEKARIA PH, Kumar A, Subramaniam D, Dunavin N, et al
    Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells.
    Leukemia. 2019 Jan 21. pii: 10.1038/s41375-018-0355.
    PubMed     Text format     Abstract available


  21. DODERO A, Guidetti A, Tucci A, Barretta F, et al
    Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma.
    Leukemia. 2019 Jan 10. pii: 10.1038/s41375-018-0320.
    PubMed     Text format    


  22. THURNER L, Hartmann S, Fadle N, Kemele M, et al
    LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting.
    Leukemia. 2019;33:148-158.
    PubMed     Text format     Abstract available


  23. ANASTASIADOU E, Stroopinsky D, Alimperti S, Jiao AL, et al
    Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
    Leukemia. 2019;33:132-147.
    PubMed     Text format     Abstract available


    December 2018
  24. EDGINTON-WHITE B, Cauchy P, Assi SA, Hartmann S, et al
    Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0311.
    PubMed     Text format     Abstract available


  25. PENG RJ, Han BW, Cai QQ, Zuo XY, et al
    Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0324.
    PubMed     Text format     Abstract available


    October 2018
  26. FRASER G, Cramer P, Demirkan F, Silva RS, et al
    Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0276.
    PubMed     Text format     Abstract available


  27. HOUOT R, Cartron G, Bijou F, de Guibert S, et al
    Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0282.
    PubMed     Text format    


    August 2018
  28. PRUTSCH N, Gurnhofer E, Suske T, Liang HC, et al
    Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
    Leukemia. 2018 Aug 21. pii: 10.1038/s41375-018-0239.
    PubMed     Text format     Abstract available


  29. BORCHMANN S, Muller H, Haverkamp H, Baues C, et al
    Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG).
    Leukemia. 2018 Aug 21. pii: 10.1038/s41375-018-0240.
    PubMed     Text format     Abstract available


    April 2018
  30. HU T, Wu Q, Chong Y, Qin H, et al
    FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.
    Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0124.
    PubMed     Text format     Abstract available


    March 2018
  31. SCHLEUSSNER N, Merkel O, Costanza M, Liang HC, et al
    The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.
    Leukemia. 2018 Mar 28. pii: 10.1038/s41375-018-0045.
    PubMed     Text format     Abstract available


  32. SUN W, Malvar J, Sposto R, Verma A, et al
    Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
    Leukemia. 2018 Mar 15. pii: 10.1038/s41375-018-0094.
    PubMed     Text format     Abstract available


    February 2018
  33. GALLARDO F, Bertran J, Lopez-Arribillaga E, Gonzalez J, et al
    Novel phosphorylated TAK1 species with functional impact on NF-kappaB and beta-catenin signaling in human Cutaneous T-cell lymphoma.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0066.
    PubMed     Text format     Abstract available


  34. ARAF S, Wang J, Korfi K, Pangault C, et al
    Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.
    Leukemia. 2018 Feb 8. pii: 10.1038/s41375-018-0043.
    PubMed     Text format    


  35. NAIRISMAGI M-, Gerritsen ME, Li ZM, Wijaya GC, et al
    Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0004.
    PubMed     Text format     Abstract available


  36. RULE S, Jurczak W, Jerkeman M, Rusconi C, et al
    Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0023.
    PubMed     Text format    


  37. KLYMENKO T, Bloehdorn J, Bahlo J, Robrecht S, et al
    Lamin B1 regulates somatic mutations and progression of B-cell malignancies.
    Leukemia. 2018;32:364-375.
    PubMed     Text format     Abstract available


  38. LIU E, Tong Y, Dotti G, Shaim H, et al
    Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
    Leukemia. 2018;32:520-531.
    PubMed     Text format     Abstract available


    November 2017
  39. HARTMANN K, Illing A, Leithauser F, Baisantry A, et al
    Gene dosage reductions of Trf1 and/or Tin2 induce telomere DNA damage and lymphoma formation in aging mice.
    Leukemia. 2017 Nov 10. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  40. GERMINI D, Tsfasman T, Klibi M, El-Amine R, et al
    HIV Tat induces a prolonged MYC relocalization next to IGH in circulating B-cells.
    Leukemia. 2017;31:2515-2522.
    PubMed     Text format     Abstract available


    October 2017
  41. HU G, Dasari S, Asmann YW, Greipp PT, et al
    Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma.
    Leukemia. 2017 Oct 13. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  42. SOMMERMEYER D, Hill T, Shamah SM, Salter AI, et al
    Fully human CD19-specific chimeric antigen receptors for T-cell therapy.
    Leukemia. 2017;31:2191-2199.
    PubMed     Text format     Abstract available


  43. CHEN KH, Wada M, Pinz KG, Liu H, et al
    Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
    Leukemia. 2017;31:2151-2160.
    PubMed     Text format     Abstract available


    September 2017
  44. JIA YJ, Liu ZB, Wang WG, Sun CB, et al
    HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.
    Leukemia. 2017 Sep 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  45. VRZALIKOVA K, Ibrahim M, Vockerodt M, Perry T, et al
    S1PR1 drives a feed forward signalling loop to regulate BATF3 and the transcriptional programme of hodgkin lymphoma cells.
    Leukemia. 2017 Sep 7. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    August 2017
  46. FUJISAWA M, Sakata-Yanagimoto M, Nishizawa S, Komori D, et al
    Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma.
    Leukemia. 2017 Aug 23. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  47. ZAMO A, Pischimarov J, Schlesner M, Rosenstiel P, et al
    Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole exome sequencing.
    Leukemia. 2017 Aug 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  48. KARUBE K, Enjuanes A, Dlouhy I, Jares P, et al
    Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    July 2017
  49. CHEADLE EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, et al
    A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  50. YAO Z, Deng L, Xu-Monette ZY, Manyam GC, et al
    Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.
    Leukemia. 2017 Jul 12. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  51. JAIN N, Zhu H, Khashab T, Ye Q, et al
    Targeting nucleolin for better survival in diffuse large B-cell lymphoma.
    Leukemia. 2017 Jul 10. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    June 2017
  52. SUN B, Fiskus W, Qian Y, Rajapakshe K, et al
    BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.
    Leukemia. 2017 Jun 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  53. LOLLIES A, Hartmann S, Schneider M, Bracht T, et al
    An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
    Leukemia. 2017 Jun 29. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    May 2017
  54. KASENDA B, Ihorst G, Schroers R, Korfel A, et al
    High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma-a prospective multicentre trial by the German cooperative PCNSL study group.
    Leukemia. 2017 May 31. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    April 2017
  55. VAN DER MEULEN M, Dinmohamed AG, Visser O, Doorduijn JK, et al
    Improved survival in primary central nervous system lymphoma up to age 70 only: A population-based study on incidence, primary treatment and survival in the Netherlands, 1989-2015.
    Leukemia. 2017 Apr 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    March 2017
  56. ATSAVES V, Tsesmetzis N, Chioureas D, Kis L, et al
    PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large cell lymphoma.
    Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  57. DZIKIEWICZ-KRAWCZYK A, Kok K, Slezak-Prochazka I, Robertus JL, et al
    ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma.
    Leukemia. 2017 Mar 23. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    January 2017
  58. MONJEZI R, Miskey C, Gogishvili T, Schleef M, et al
    Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.
    Leukemia. 2017;31:186-194.
    PubMed     Text format     Abstract available


  59. RUELLA M, Kenderian SS, Shestova O, Klichinsky M, et al
    Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.
    Leukemia. 2017;31:246-248.
    PubMed     Text format    


    March 2016
  60. GONDEK LP, Zheng G, Ghiaur G, DeZern AE, et al
    Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation.
    Leukemia. 2016 Mar 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    February 2016
  61. MIRANDA MB, Lauseker M, Kraus MP, Proetel U, et al
    Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment- long-term observation in CML Study IV.
    Leukemia. 2016 Feb 9. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: